Duavee: a tissue-selective estrogen complex for menopausal symptoms and prevention of osteoporosis

Deepika Tikoo, Meenakshi Gupta


Post-menopausal women suffer from a plethora of problems like vasomotor symptoms, vulvovaginal atrophy (VVA), bone loss, and all this can be attributed to estrogen deficiency. The conventional treatment till date for these hormone deficient manifestations have been estrogen replacement therapy in hysterectomized female or a combination of estrogen and progesterone therapy in women with an intact uterus. The reason for adding progesterone is to protect the endometrium from estrogenic stimulation. The drawback with the combination therapy was irregular vaginal bleeding and breast discomfort, which led to the discontinuation of this therapy. The United States Food and Drug Administration, has recently approved a novel tissue selective estrogen complex comprising of conjugated estrogen (0.45 mg) and a selective estrogen receptor modulator, bazedoxifene (BZA) (20 mg) for the treatment of moderate to severe vasomotor symptoms and prevention of osteoporosis in non-hysterectomized post-menopausal women. This combination retains the benefits of estrogen on vasomotor symptoms, VVA and bone density along with the protective effect of BZA on endometrium and breast tissue. The results of clinical trials have been promising but what still needs to be evaluated is the long term safety of this pair on venous thromboembolism, stroke, and breast cancer.


Bazedoxifene, Conjugated estrogen, Menopause, Osteoporosis

Full Text:



Levin ER, Hammes SR. Estrogen and progestins. In: Brunton LB, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011: 1163-94.

Komm BS, Mirkin S. The tissue selective estrogen complex: a promising new menopausal therapy. Pharmaceuticals (Basel). 2012;5(9):899-924.

Komm BS, Mirkin S. Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy. Int J Womens Health. 2012;4:129-40.

Mirkin S, Pickar JH. Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination. Int J Womens Health. 2013;5:465-75.

Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms and prevention of osteoporosis. Med Lett Drugs Ther. 2014;56(1441):33-4.

Cada DJ, Baker DE. Conjugated estrogens and bazedoxifene. Hosp Pharm. 2014;49(3):273-83.

Duavee. Available at http://www.rxlist.com/duavee-drug.htm. Accessed 21 January 2015.

Gennari L, Merlotti D, Paola VD, Martini G. Bazedoxifene for the prevention of postmeopausal osteoporosis. Ther Clin Risk Manage. 2008;4(6):1229-42.

Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas. 2013;76(3):213-20.

Roger SR. Duavee (conjugated estrogens/bazedoxifene): a review. Pharma Note. 2014;29(5):1-7.

Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16(6):1116-24.

Lindahl SH. Reviewing the options for local estrogen treatment of vaginal atrophy. Int J Womens Health. 2014;6:307-12.

Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92(3):1018-24.

Pfizer Inc. Announces FDA approval of Duavee (conjugated estrogens/bazedoxifene) for the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause and the prevention of postmenopausal osteoporosis. Available at http://www.press.pfizer.com/press-release/pfizer-inc-announces-fda-approval-duavee-conjugated-estrogens-bazedoxifene-treatment-m. Accessed 21 January 2015.

Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women’s Health Initiative Memory Study. JAMA. 2004;291(24):2947-58.